Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Growth hormone therapy in achondroplasia.

Hormone research - 1 Jan 2000

Seino Y, Yamanaka Y, Shinohara M, Ikegami S, Koike M, Miyazawa M, Inoue M, Moriwake T, Tanaka H

Abstract excerpt

Achondroplasia is one of the most common causes of severe rhizomelic dwarfism. We have previously reported the growth-promoting effect of growth hormone (GH) in this disorder. In this expanded clinical study, dose dependency and the long-term effect of GH were also investigated. Prepubertal children with achondroplasia (82 males and 63 females) were randomly divided into 2 groups. Patients were treated with 0.5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Achondroplasia
Share to Body Height
Share to Bone Development

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Growth Hormone

Share to Insulin-Like Growth Factor Binding Protein 3

Share to Insulin-Like Growth Factor I

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Receptors, Fibroblast Growth Factor

Source

Identifiers

PMID: 10971105
DOI: 10.1159/000023534

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Growth hormone therapy in achondroplasia.PMID 10971105Read ↗

Effect of growth hormone therapy in children with achondroplasia: growth pattern, hypothalamic-pituitary function, and genotype.Semantic proximity Read ↗

Molecular defects in achondroplasia and the effects of growth hormone treatment.Semantic proximity Read ↗

Growth hormone therapy in achondroplasiaSemantic proximity Read ↗

Novel therapeutic approaches for the treatment of achondroplasia.Semantic proximity Read ↗

Update in growth hormone therapy of children.Semantic proximity Read ↗

Fibroblast Growth Factor Receptor-3 as a Therapeutic Target for Achondroplasia - Genetic Short Limbed DwarfismSemantic proximity Read ↗

A pilot study of discontinuous, insulin-like growth factor 1-dosing growth hormone treatment in young children with FGFR3 N540K-mutated hypochondroplasia.Semantic proximity Read ↗

Achondroplasia: pathogenesis and implications for future treatment.Semantic proximity Read ↗

Growth Hormone Therapy in Children with Kabuki Syndrome: 1-year Treatment Results.Semantic proximity Read ↗

Improved growth velocity of a patient with Noonan-like syndrome with loose anagen hair (NS/LAH) without growth hormone deficiency by low-dose growth hormone therapy.Semantic proximity Read ↗

Evaluation of Volumetric Bone Mineral Density, Bone Microarchitecture, and Bone Strength in Patients with Achondroplasia Caused by FGFR3 c.1138G > A Mutation.Semantic proximity Read ↗

Increased p21 expression in chondrocytes of achondroplasic children independently from the presence of the G380R FGFR3 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.